Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - febuxostat - film-coated tablet - 80 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - febuxostat - film-coated tablet - 80 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

Kenya - English - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no. 1 - febuxostat - tablet - febuxostat 80mg - febuxostat

Kenya - English - Pharmacy and Poisons Board

sunberg lifesciences pvt ltd no.15, gopalakrishna road, t-nagar, chennai 600 - febuxostat 80mg - tablet - febuxostat 80mg - febuxostat

Kenya - English - Pharmacy and Poisons Board

dawa limted plot no.7879/8.baba dogo road,ruaraka.p.o box - febuxostat - tablet - febuxostat 80mg per tablet - febuxostat

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat 40 mg - uloric is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. limitations of use : uloric is not recommended for the treatment of asymptomatic hyperuricemia. uloric is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with uloric use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adverse developmental effects were observed in

United States - English - NLM (National Library of Medicine)

cardinal health - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat 40 mg - uloric is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. for the safe and effective use of allopurinol, see allopurinol prescribing information. limitations of use : uloric is not recommended for the treatment of asymptomatic hyperuricemia. uloric is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with uloric use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the m

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat 40 mg - uloric is a xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. uloric is not recommended for the treatment of asymptomatic hyperuricemia. uloric is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with uloric use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adverse developmental effects were observed in a pre- and postnatal development study with administration of febuxostat to pregnant rats from organogenesis through lactation at an exposure approximately 11 times the mrhd (see data) . the esti